Assuming a 30% test adoption rate, we estimate the potential US market for ConfirmMDx in excess $1 billion and we estimate the potential global market opportunity to be greater than $2 billion.
Assuming a 30% test adoption rate, we estimate the potential EU and US market for SelectMDx opportunity to be greater than $1 billion
We believe that our proprietary, accurate and scalable epigenetic technologies provide MDxHealth with a key competitive advantage in the diagnosis, prognosis and management of cancer. In addition to our ongoing and planned studies to expand the clinical utility of ConfirmMDx for Prostate Cancer, our product pipeline includes tests for bladder, kidney and other urologic cancers. For other cancer types, we have engaged partners to commercialize our epigenetic technologies, as shown by the successful launches of Cologuard® for colon cancer by licensee Exact Sciences and PredictMDx® for Glioblastoma by licensee Laboratory Corporation of America (Labcorp).
Toekomstige waarde MdxHealth tussen 15 en 47 euro per aandeel laat zich zien,